



FINANCIAL TEAR SHEET

CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

STOCK MARKET DATA

ERYP.PA (Common Stock)

Exchange	Paris (Euro)
Price	€28.25
Change (%)	▼ 0.7 (2.42%)
Volume	49,915
52 Week Low	€11.50
Market Cap	€251,238,283
Rolling EPS	-2.94
PE Ratio	0

Shares Outstanding 8,732,648

Data as of 06/27/17 5:35 p.m. ET



RECENT NEWS & EVENTS

	Date	Title
07-Jun-2017 ERYTECH Pharma: Annual General Meeting of June 27, 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2279437)	06/27/17 9:30 a.m. CET	General Meeting of Shareholders (phoenix.zhtml?c=254271&p=irol-EventDetails&EventId=5247803)
05-Jun-2017 ERYTECH Pharma: Information related to total number of voting rights and shares composing the share capital –May 31st, 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2278852)	09/11/17	Location Paris, France Second Quarter and Half-Year 2017 Financial Results and Business Update: Press Release: Monday, September 11, 2017 (after market)
18-May-2017 ERYTECH Provides Business Update and Financial Highlights For Q1 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2274066)	09/12/17 3:00 p.m. CET	Second Quarter and Half-Year 2017 Financial Results and Business Update: Conference Call (phoenix.zhtml?c=254271&p=irol-EventDetails&EventId=5247800)

SEC FILINGS

Filing Date Form

12/22/15	D (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa)
01/09/15	EFFECT (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vc)
12/29/14	F-6 (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa)
11/10/14	D/A (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa)